XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Beginning balance (in shares) at Mar. 31, 2022   6,889,400      
Beginning balance at Mar. 31, 2022 $ 64,716 $ 7 $ 336,281 $ (3,968) $ (267,604)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 3,336   3,336    
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan (in shares)   5,167      
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan $ 63   63    
Net proceeds from exercise of stock options for cash (in shares) 3,646        
Issuance of common stock upon exercise of options (cashless) (in shares)   3,700      
Issuance of common stock upon exercise of options for cash $ 104   104    
Increase in fair value attributed to warrant modifications $ 78   78    
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses (in shares) 413,670        
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition, net of registration expenses $ 3,031   3,031    
Net loss (59,248)       (59,248)
Ending balance (in shares) at Mar. 31, 2023   7,315,583      
Ending balance at Mar. 31, 2023 12,080 $ 7 342,893 (3,968) (326,852)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 2,182   2,182    
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan (in shares)   4,843      
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan $ 8   8    
Issuance of common stock upon exercise of options (cashless) (in shares) 0        
Issuance of common stock under Open Market Sale Agreement, net of issuance costs (in shares)   4,698,495      
Issuance of common stock under Open Market Sale Agreement, net of issuance costs $ 35,899 $ 5 35,894    
Issuance of common stock and pre-funded warrants through public offering, net of issuance costs (in shares) 15,010,810        
Issuance of common stock and pre-funded warrants through public offering, net of issuance costs $ 93,479 $ 15 93,464    
Net loss (29,362)       (29,362)
Ending balance (in shares) at Mar. 31, 2024   27,029,731      
Ending balance at Mar. 31, 2024 $ 114,286 $ 27 $ 474,441 $ (3,968) $ (356,214)